Toronto Dominion Bank
RLMD icon

Toronto Dominion Bank’s Relmada Therapeutics RLMD Stock Holding History

Toronto Dominion Bank’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74
Closed -$306 – 1584
2023
Q4 		$306 Sell
74
-7
-9% -$21 ﹤0.01% 1383
2023
Q3 		$243 Hold
81
– – ﹤0.01% 1577
2023
Q2 		$0 Buy
+81
New +$224 ﹤0.01% 1747

Other funds holding RLMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Toronto Dominion Bank's RLMD Position: Q1 2024 in Review

Toronto Dominion Bank sold out of Relmada Therapeutics (RLMD) in Q1 2024, closing a stake of 74 shares — an estimated $306 sold.

Toronto Dominion Bank first reported a position in RLMD in Q2 2023 and held it in 3 quarters. The position peaked at $306 in Q4 2023. 93 funds tracked by Wall St. Rank hold RLMD as of Q1 2024.

  • Toronto Dominion Bank reported no remaining Relmada Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Toronto Dominion Bank sold 74 Relmada Therapeutics shares in Q1 2024, an estimated $306.
  • Toronto Dominion Bank first reported a position in Relmada Therapeutics in Q2 2023 and held it in 3 quarters.
  • Toronto Dominion Bank's Relmada Therapeutics position peaked at $306 in Q4 2023.
  • 93 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2024.

Based on Toronto Dominion Bank's 13F filing for Q1 2024, filed 14 May 2024.